Dear Voornaam Welcome to your weekly Cancer Research UK Research Update email. Today I am pleased to announce were making a multi-million-pound investment in TRACERx EVO, the next phase of our flagship lung cancer study TRACERx. Charles Swanton, Sergio Quezada and Caroline Dive will co-lead an international consortium of researchers in four countries, with workstreams led by Caroline, Nicholas McGranahan, Emilia Lim, Erik Sahai, Julian Downward and Mariam Jamal-Hanjani. Since 2014, TRACERx has greatly developed our understanding of lung cancer, from tumour evolution to drug response. The team have published 18 high-impact papers already, a further 90 publications are based on TRACERx data, and it has established over 100 collaborations. The programme has leveraged over 200m from industry and thats just so far. The sheer amount of data the project has collated will, Im sure, see researchers continue to make discoveries and breakthroughs for many years to come. With patient recruitment for TRACERx coming to an end, Charlie, Sergio and Caroline are looking ahead. Over the next seven years TRACERx EVO will continue to transform the field of lung cancer research through sharing data, developing new technologies, and training future leaders in lung cancer research. By building on the collective understanding of lung cancer evolution, drug resistance, metastasis and immune evasion, the team wants to develop rapid advancements in therapeutic strategies in this disease. This is a significant investment for Cancer Research UK which underscores our commitment to lung cancer research. The findings that have emerged from TRACERx so far have exceeded expectations I am excited about the advances in patient impact that could come from this next phase. Kind regards, Iain Foulkes Executive Director Research & Innovation CEO Cancer Research Horizons Cancer Research UK |
|
---|
|
---|
|
|
Funding & Research Opportunities |
|
---|
|
---|
| Applications accepted all-year round |
|
---|
|
---|
| Applications accepted all-year round |
|
---|
|
---|
|
|
TACKLING DIVERSITY IN DATA SCIENCE With cancer research becoming increasingly data-driven, we need a diverse and inclusive data science workforce to reflect the needs of the whole community. Anastacia, Kafayat, Phinehas and Fisayo joined this years cohort of Health Data Science Black Interns and were hosted by Cancer Research UK. We caught up with these incredibly talented interns to hear more about their experience in the programme. The internship provided a confidence boost for Anastacia, helped Kafayat improve her technical approach, created strong ties for Phinehas in his future career path, and was overall an experience that Fisayo hopes more people can have in future. |
|
---|
| BECOME AN INTERN HOST Health Data Research UK set up the Health Data Science Black Internship programme to help address both the urgent need for new health data scientists and the under-representation of Black scientists in the field. 2023 programme applications are now open and theyre calling for host organisations to join. Hear more about what being a host entails in their webinar 29 November at 1PM GMT. |
|
---|
|
---|
|
|
THE KQ LABS FIFTH COHORT HAS BEEN ANNOUNCED Cancer Research Horizons is excited to sponsor RareCan Limited, the only health tech company in the UK that specialises in supporting patients with rare cancers, as part of a new cohort of start-up companies hosted at the Francis Crick Institute. KQ Labs is an accelerator programme for early-stage start-ups using software and data science as a core part of their business model to improve human health. Each year Cancer Research Horizons sponsors one promising KQ Labs start-up to further its cutting-edge innovation to beat cancer. RareCan, along with the other nine companies, will be offered weekly workshops and access to personalised mentoring and coaching. They will also benefit from funding and introductions to key investors and major corporations. |
|
---|
|
---|
|
|
6 HIGHLIGHTS FROM THE BLACK IN CANCER CONFERENCE Weve been reflecting on the great sense of connection and collaboration coming out of the Black in Cancer conference last month. Here are six of our top learnings from the event, including the value of representation in research and how to make a difference in improving cancer outcomes for everyone. Tell us what you think of these top takes or let us know your highlights using #BiCconf22 on Twitter. |
|
---|
|
---|
|
|
SUPPORTING BEHAVIOURAL RESEARCH APPLICATIONS Join Kate Brain, Mark Tully and Katie Robb, members of the Prevention and Population and the Early Detection and Diagnosis Research Committees, for a webinar at 1pm GMT on 29 November for insights into our research strategy, opportunities for behavioural scientists, and how to develop your application. Were keen to help behavioural scientists submit more and higher quality applications to increase their chances of securing funding. |
|
---|
| SIDE BY SIDE IN NATURE: EPIGENETICS CAN SHAPE CANCER BEHAVIOUR AND TREATMENT Scientists at the Institute of Cancer Research, Human Technopole and Queen Mary University of London have shown epigenetics plays an important role in the development of bowel cancers. The studies, funded by our Accelerator Award, suggest factors other than DNA mutations can drive cancer evolution resulting in more aggressive disease. Heide et al looked at epigenetic changes as cancers evolved, while Househam et al aimed to understand why cancer cells within the same tumour can be so different to one another. The research findings could explain why DNA tests dont always predict how cancers will respond to treatment and why some environmental exposures can cause cancer without leading to mutations in the DNA code. These advances could lead to new forms of tests and help tailor cancer treatments. |
|
---|
|
---|
|
|
| London, UK 14 November 2022 |
|
---|
|
---|
| Manchester, UK 15 November 2022 |
|
---|
|
---|
| Online 2:00 PM 23 November 2022 |
|
---|
|
---|
| Online 1:00 PM 29 November 2022 |
|
---|
|
---|
| Online 1:00 PM 29 November 2022 |
|
---|
|
---|
| East Sussex, UK 04 December 2022 |
|
---|
|
---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
---|
|
---|
|
|
Been forwarded this email? Subscribe to our newsletter to stay up-to-date. |
---|
| |
---|
|
|
|